Sun Wenjia, Zhou Jianya, Zhou Jianying
Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310000, China.
Zhongguo Fei Ai Za Zhi. 2021 Jan 20;24(1):36-42. doi: 10.3779/j.issn.1009-3419.2020.102.47.
Lung cancer is the most common malignancy and is a major public health problem worldwide. Programmed cell death receptor 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors provide a new treatment strategy for non-small cell lung cancer (NSCLC). The existing biomarkers all have advantages and defects in selecting patients who benefit from immunotherapy. The multiplex immunohistochemistry/immunofluorescence (mIHC/IF) provides multiplex staining, allows comprehensive studies of cellular composition, cellular functions and cell-cell interactions. A number of studies have used mIHC/IF to explore specific immune cells in tumor immune microenvironment (TIME) and found that it is helpful for clinical prognosis and efficacy prediction in patients with lung cancer. In the era of immunotherapy for lung cancer, this technique has a bright future in translational research and clinical practice. The research progress of mIHC/IF detection in lung cancer immunotherapy is summarized in this review. .
肺癌是最常见的恶性肿瘤，也是全球主要的公共卫生问题。程序性细胞死亡受体1（PD-1）/程序性细胞死亡配体1（PD-L1）抑制剂为非小细胞肺癌（NSCLC）提供了一种新的治疗策略。现有的生物标志物在选择从免疫治疗中获益的患者方面都有优点和缺陷。多重免疫组化/免疫荧光（mIHC/IF）提供多重染色，允许对细胞组成、细胞功能和细胞间相互作用进行全面研究。一些研究已使用mIHC/IF来探索肿瘤免疫微环境（TIME）中的特定免疫细胞，并发现其有助于肺癌患者的临床预后和疗效预测。在肺癌免疫治疗时代，该技术在转化研究和临床实践中有着光明的前景。本文综述了mIHC/IF检测在肺癌免疫治疗中的研究进展。
